Analysis

Jasper Therapeutics, Inc. (JSPR) Stock Analysis

Jasper Therapeutics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to JSPR.

websiteJSPR/analysis/JSPR

Jasper Therapeutics, Inc.

Jasper Therapeutics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to JSPR.

Stock profile

Ticker

JSPR

Asset type

Stock

Market cap

$12.7M

Sector

Health Technology

Industry

Biotechnology

Currency

USD

Ticker listings

Jasper Therapeutics, Inc. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • JSPR primary listing

Latest Jasper Therapeutics, Inc. news

Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

REDWOOD CITY, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briqui...

Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update

REDWOOD CITY, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on

Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference

REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briqu...

Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria

67% of additional patients (n=6) enrolled in the BEACON study achieved a complete response at 12 weeks with a mean UAS7 reduction of 31 points 75% of CSU participants (n=36) enr...

Research sections

Valuation

Review valuation context for Jasper Therapeutics, Inc..

Future growth

Review future growth context for Jasper Therapeutics, Inc..

Past performance

Review past performance context for Jasper Therapeutics, Inc..

Financial health

Review financial health context for Jasper Therapeutics, Inc..

Dividend

Review dividend context for Jasper Therapeutics, Inc..

Management

Review management context for Jasper Therapeutics, Inc..

Ownership

Review ownership context for Jasper Therapeutics, Inc..

Other information

Review other information context for Jasper Therapeutics, Inc..

Community

Review community context for Jasper Therapeutics, Inc..